the Canberra NICU were alerted an infant was colonised for VRE on screening after transfer to a stepdown unit. Screening of all infants identified a 20% colonisation rate.
Grace Centre for Newborn Care, The Children's Hospital at Westmead, Sydney, Australia Email: krystal.carman@health.nsw.gov.au Background: Intravenous glucagon infusions have been used to manage severe and refractory neonatal hypoglycaemia for many years but there is little evidence based information available, and the few published studies have had varied results.
Aims: To investigate the response and efficacy of glucagon in the treatment of neonatal hypoglycaemia, and to identify those patients who respond well and would benefit from early glucagon commencement.
Methods: A retrospective observational study identified neonates who received glucagon infusions during a 16 year period (n=137). Blood glucose levels prior, during and after glucagon infusions, times to achieve normoglycaemia, causes of hypoglycaemia, response to glucagon, glucose infusion rates and glucagon requirement were analysed. Complications including recurrent hypoglycaemia, endocrine profile, hyponatremia and thrombocytopenia were also examined.
Results: Glucagon infusions rapidly increased blood glucose levels, achieving normoglycaemia within 2 hours of commencement in 84.7% of patients, and within 4 hours in 93.4%. These results were equivalent across all causes of hypoglycaemia. Glucagon infusion requirements were 5-20 micrograms/kilogram/ hour and duration ranged from 5 hours to 14 weeks. 54% of patients had 3 or more hypoglycaemic causative factors, the most common being perinatal stress (63.5%), IUGR (41.6%) and undergoing a surgical procedure (40.1%). 96.9% of the study population were inappropriately hyperinsulinaemic.
Conclusions: Glucagon infusions used for severe refractory neonatal hypoglycaemia achieve normoglycaemia rapidly and are efficacious across all causes of hypoglycaemia. Background: Preeclampsia is a life threatening disease specific to human pregnancy and affects 3-5% of pregnancies worldwide. Antiphospholipid autoantibodies (aPLs) increase a woman's risk of preeclampsia 10 fold but how is not fully understood. Previous work showed that aPLs disrupt mitochondrial activity in the syncytiotrophoblast resulting in the extrusion of toxic extracellular vesicles which induce maternal endothelial cell activation. Mitochondria are regulators of cell death via activation of caspases and here we investigated whether the activity of caspase 3, 8 and 9 is altered in placental explants that had been exposed to aPLs.
THE INCREASED ACTIVITY OF CASPASES
Methods: Explants dissected from first trimester placenta were treated with monoclonal aPLs, ID2 (25μg/ml, 50μg/ml) and IIC5 (25μg/ml, 50μg/ml), as well as control antibody, IgG (25μg/ml, 50μg/ml) for 3 hours or overnight. The activity of caspase 3/7, 8 and 9 in placental explants was measured by FLICA fluorescent kit.
Results: The activity of caspases 8 and 9, but not caspase 3, were increased in the syncytiotrophoblast 3 hours after exposure to either ID2 or IIC5, compared with antibody controls. In contrast the activity of caspase 3 in the syncytiotrophoblast was increased in explants 18 hours after exposure to ID2 or IIC5, relative to controls.
Conclusions: Our data demonstrate that aPLs activate the cell death machinery in placental syncytiotrophoblast and this likely increases production of toxic cellular debris that is extruded from the placenta in preeclampsia. This may be one of the mechanisms by which maternal aPL increases a woman's risk of developing preeclampsia. 
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